Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Medicine of older adults indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Lewy body and Parkinson disease dementia

Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Neuroleptic sensitivity or acute delirium

Profound rigidity, dysphagia, reduced consciousness, fever or autonomic instability after an antipsychotic may be life-threatening; acute fluctuation from infection, pain or medicines must not be mistaken for ordinary Lewy-body variability.

Action: Stop the suspected dopamine blocker, assess airway, aspiration, temperature, CK, renal function and autonomic status, treat possible neuroleptic malignant syndrome and acute causes, and involve geriatric, neurological and critical-care expertise urgently.

Overview

Recognise the Lewy-body cognitive, visual, sleep, motor and autonomic phenotype, use chronology to distinguish DLB from Parkinson disease dementia, prevent neuroleptic harm and balance cognitive, mobility, function and carer priorities.

Ask separately about cognition, visions, motor timing, sleep and autonomic symptoms. The recurrent visions commonly depict fully formed people or animals; insight that they are not real may be preserved early. Fluctuation means marked variation in attention, speech or alertness rather than ordinary good and bad days. Ask a bed partner about dream enactment and injuries and establish when bradykinesia began relative to cognitive functional loss.

Examine attention, executive and visuospatial function, eye movements, rigidity, bradykinesia, tremor, gait and postural blood pressure. Assess vision, hearing and medication exposure. Record IADLs and ADLs and how fluctuation affects supervision. A normal brief amnestic screen can miss early visuoperceptual and executive disease.

Use standard dementia blood work and structural imaging to exclude lesions and assess mixed Alzheimer or vascular disease. MRI may show less medial-temporal atrophy than expected for the cognitive severity. When clinical uncertainty persists, 123I-FP-CIT SPECT demonstrating reduced striatal dopamine-transporter uptake supports probable DLB; a normal scan does not end all expert consideration.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Medicine of older adultsOriginal SBA

Recognising DLB

A patient develops recurrent detailed visual hallucinations, marked attention fluctuation and REM-sleep dream enactment; mild bradykinesia appears around the same time as functional cognitive decline. Which diagnosis best fits?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Medicine of older adults topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG97 dementia recommendationsDLB diagnosis, DAT imaging, cognitive and antipsychotic treatment.
  • NICE NG71 Parkinson disease recommendationsParkinson dementia, psychosis, levodopa and non-motor care.
  • MHRA haloperidol safety reminderDLB and Parkinson contraindication and toxicity.
  • Exelon European product informationRivastigmine dosing, titration, patch and adverse effects.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Polysomnography showing REM sleep without atonia is an indicative biomarker when the history is unclear. Cardiac MIBG and quantitative EEG are specialised and not routine UK assessment. Always distinguish chronic fluctuation from superimposed delirium with 4AT, physiology, medicines and collateral baseline.

Donepezil and rivastigmine can improve cognition, global function and hallucination or apathy in some people. Check pulse, syncope, conduction, weight, GI and interaction risk and titrate slowly. Memantine is considered when AChE inhibitors are not tolerated or contraindicated, with renal adjustment and a defined target.

Review Parkinson medicines with a specialist, removing drugs most likely to worsen hallucinations only when motor and withdrawal consequences are considered. Low-dose levodopa may support transfers and walking but often produces less motor gain than in ordinary Parkinson disease. Treat constipation, posture, urinary symptoms, pain and sleep without adding avoidable anticholinergic burden.

Hallucinations that are benign and understood may need reassurance, lighting and visual optimisation rather than medication. When psychosis creates severe distress or danger, exclude delirium and unmet need and use specialist advice. DLB sensitivity makes haloperidol contraindicated; even quetiapine or clozapine has limited evidence, sedation, hypotension and mortality risk.

Support carers with explanation that fluctuation is disease-related, strategies for hallucinations and dream enactment, safe transfers and medication timing. Assess driving, finances, falls, swallowing, home and decision-specific capacity. Advance planning should occur during clearer periods while respecting that performance variability does not equal permanent incapacity.

Key points

  • Core DLB features are recurrent well-formed visual hallucinations, marked cognitive fluctuation, spontaneous parkinsonism and REM-sleep behaviour disorder.
  • Use the one-year convention: DLB when dementia precedes or occurs within one year of parkinsonism; Parkinson disease dementia when cognitive decline follows established Parkinson disease by more than one year.
  • Early attention, executive and visuoperceptual deficits may dominate while memory storage appears less impaired than in typical Alzheimer disease.
  • Supportive clues include severe antipsychotic sensitivity, autonomic dysfunction, falls, syncope, hyposmia, depression and relative medial-temporal preservation.
  • First-line diagnosis remains clinical with collateral; dopamine-transporter SPECT supports DLB when parkinsonism or subtype remains uncertain.
  • Treat acute change as possible delirium and review anticholinergics, dopamine blockers, sedatives and Parkinson medicine timing.
  • NICE recommends donepezil or rivastigmine for mild-to-moderate DLB; consider them in severe DLB and for Parkinson disease dementia under specialist care.
  • Rivastigmine oral treatment begins 1.5 mg twice daily with food and increases no more often than every two weeks according to tolerance.
  • Levodopa may improve disabling motor symptoms but can worsen hallucination or posture; use a low specialist dose against a functional goal.
  • Avoid haloperidol. Antipsychotic use is exceptional, specialist-led, lowest-dose and shortest-duration because all options retain serious risk.

Aetiology

01

Alpha-synuclein disease

Misfolded alpha-synuclein aggregates in neurons and processes as Lewy bodies and neurites across brainstem, limbic and cortical regions.

02

Age and susceptibility

Age, male sex and genetic variants including GBA and SNCA alter risk, but most late-life disease is sporadic and routine genetic testing is unnecessary.

03

Parkinson continuum

The same pathological spectrum can begin with dementia or with established motor Parkinson disease, with chronology determining the clinical label.

04

Mixed Alzheimer pathology

Amyloid and tau frequently coexist and can increase amnesia, progression and imaging overlap. This increases vulnerability across cognition, function and daily care.

Pathophysiology

  1. 1
    Cortical network fluctuation

    Variable attention and arousal arise from unstable cortical and thalamic networks, producing striking hour-to-hour cognitive performance differences.

  2. 2
    Visual processing disruption

    Occipital and visuoperceptual dysfunction contributes to recurrent detailed hallucinations, misidentification and navigation difficulty. This influences cognition, mobility and everyday functional reserve.

  3. 3
    Nigrostriatal dopamine loss

    Degeneration of substantia-nigra pathways causes bradykinesia, rigidity and gait impairment while making dopamine blockade hazardous. This influences cognition, mobility and everyday functional reserve.

  4. 4
    Cholinergic deficit

    Marked basal-forebrain cholinergic loss supports both cognitive symptoms and responsiveness to cholinesterase inhibitors. This influences cognition, mobility and everyday functional reserve.

  5. 5
    Autonomic and sleep-system injury

    Peripheral and brainstem synuclein pathology causes posture symptoms, constipation, urinary dysfunction and REM sleep without normal atonia.

Clinical features and red flags

Formed visual hallucinations

Recurrent people, children or animals are seen in detail, often with variable insight and environmental triggers.

Pronounced cognitive fluctuation

Attention, coherence and alertness vary strikingly over minutes or hours and require collateral description.

Spontaneous parkinsonism

Bradykinesia with rigidity or rest tremor occurs without dopamine-blocking exposure.

REM-sleep behaviour

Dream enactment, shouting or striking during sleep may precede cognitive and motor symptoms by years.

Neuroleptic sensitivityRed flag

Severe rigidity, dysphagia, somnolence or autonomic decline follows dopamine blockade and is an emergency.

Autonomic-motor riskRed flag

Postural hypotension, syncope, constipation, urinary dysfunction and falls interact with treatment and function.

Red flags requiring action

  • Haloperidol and other potent dopamine blockers can cause severe or fatal sensitivity and should be avoided in DLB and Parkinson disease.
  • Acute inattention, drowsiness or new immobility still requires 4AT and a delirium cause search despite baseline cognitive fluctuation.
  • Syncope, recurrent falls, postural hypotension and bradycardia may reflect autonomic disease, AChE treatment or interacting medicines.
  • Dream enactment can injure the person or bed partner and requires environmental safety and specialist sleep assessment.
  • New dysphagia, weight loss, aspiration or medication-timing failure requires urgent swallowing, nutrition and Parkinson-team review.
  • Sudden focal deficit or rapid progression is atypical for routine Lewy-body course and needs alternative neurological assessment.

Investigations

  1. 01
    Collateral chronologyFirst step
    Why
    Apply phenotype and one-year convention.
    Interpretation and limitations
    Date hallucinations, fluctuation, dream enactment, IADL decline and spontaneous motor symptoms relative to established Parkinson disease.
  2. 02
    Cognitive, motor and autonomic examination
    Why
    Characterise the multisystem syndrome. within a safe older-adult assessment.
    Interpretation and limitations
    Test attention and visuospatial function, parkinsonism, gait, eye movement, posture pressure, swallow and sensory status.
  3. 03
    4AT and acute-cause screen
    Why
    Detect superimposed delirium. within a safe older-adult assessment.
    Interpretation and limitations
    Use recent-change evidence, physiology, medicines and targeted medical tests whenever fluctuation exceeds the established pattern.
  4. 04
    MRI or CT brain
    Why
    Exclude lesions and assess mixed pathology.
    Interpretation and limitations
    Review vascular burden and atrophy pattern; relative medial-temporal preservation supports but does not prove DLB.
  5. 05
    Dopamine-transporter SPECT
    Why
    Support subtype when clinical uncertainty remains.
    Interpretation and limitations
    Reduced striatal uptake is an indicative DLB biomarker; interpretation belongs within specialist phenotype assessment.
  6. 06
    Polysomnography
    Why
    Confirm REM-sleep behaviour when necessary.
    Interpretation and limitations
    REM sleep without atonia provides indicative biomarker evidence and helps distinguish mimics or unsafe nocturnal events.
  7. 07
    Medicine and cardiac review
    Why
    Prepare safe cognitive and motor treatment.
    Interpretation and limitations
    Check pulse, ECG indication, weight, posture, anticholinergics, dopamine blockers, sedatives and precise Parkinson medicine timing.

Differential diagnosis

01

Delirium

Acute change from infection, dehydration, pain or medicine effects can overlay chronic fluctuation and requires a dated collateral comparison.

02

Alzheimer disease

Early dominant episodic-memory encoding loss without hallucination, REM-sleep behaviour or parkinsonism favours Alzheimer disease, though mixed pathology occurs.

03

Vascular cognitive impairment

Stepwise focal and executive-gait change with vascular imaging burden may mimic motor and cognitive features. Distinguish it through chronology, examination and targeted testing.

04

Drug-induced parkinsonism

Dopamine blockers cause symmetrical motor signs and can unmask Lewy-body vulnerability; timing and withdrawal response assist interpretation.

05

Primary psychiatric or visual disease

Late psychosis, Charles Bonnet syndrome and severe visual impairment can cause hallucinations but lack the full cognitive-motor-sleep phenotype.

Management

01Diagnostic sequenceIntegrate cognition, visions, sleep and motor timingFirst stepLewy-body disease is suspected. within the current clinical context.+
  1. 1Obtain collateral on core features and one-year chronology and exclude delirium, visual and medicine mimics.
  2. 2Complete cognitive, neurological, autonomic, blood and structural imaging assessment.
  3. 3Use dopamine-transporter SPECT or polysomnography when specialist uncertainty would change diagnosis or care.
02First-line cognitive treatmentUse cholinesterase therapy with motor-autonomic safeguardsFirst lineMild-to-moderate DLB or Parkinson dementia is diagnosed.+
  1. 1Check pulse, syncope, posture, weight, GI and interaction risk and agree cognitive, functional or distress targets.
  2. 2Start donepezil or rivastigmine at the licensed initial dose and titrate slowly under specialist or shared care.
  3. 3Review cognition, hallucination, ADLs, falls, pulse and weight and consider memantine only when AChE treatment is unsuitable.
03Psychosis and distress routeAvoid neuroleptic catastropheHallucination or delusion becomes distressing or dangerous.+
  1. 1Search delirium, pain, environment, vision and medication triggers and use reassurance, lighting and familiar support.
  2. 2Avoid haloperidol and seek specialist review before any antipsychotic because severe sensitivity and mortality risk persist.
  3. 3Use the lowest selected dose for the shortest time with explicit target and close swallow, posture, motor and arousal monitoring.
04Motor and function routeBalance mobility against hallucination and postureParkinsonism limits transfers, walking or personal care.+
  1. 1Optimise therapy, aids, exercise, swallow and home environment and treat posture and constipation contributors.
  2. 2Use a low specialist levodopa regimen only against a meaningful mobility target.
  3. 3Review hallucinations, sleepiness, posture, falls and carer workload after every motor-treatment change.
Key medicines and prescribing safety3 treatments · regimens, roles and cautions+
One NICE-supported AChE inhibitor for mild-to-moderate DLB and specialist cognitive treatment in Parkinson disease dementia.

Rivastigmine

Start 1.5 mg orally twice daily with food and increase in 1.5 mg twice-daily steps no more often than every two weeks toward the lowest effective tolerated dose.

Check pulse, syncope, conduction, posture, weight and GI effects; medication errors occur between oral and patch formulations, which are not dose-for-dose interchangeable.

Consider when AChE inhibitors are not tolerated or contraindicated, with a defined cognitive, functional or behavioural target.

Memantine

Begin 5 mg orally once daily and increase by 5 mg each week toward 20 mg daily if tolerated, with a lower maximum in significant renal impairment.

Monitor dizziness, constipation, somnolence, blood pressure and confusion and do not expect treatment to remove neuroleptic sensitivity.

Selected disabling parkinsonism where functional benefit is likely to outweigh hallucination and postural risk.

Co-beneldopa

A specialist may begin 12.5/50 mg orally once to three times daily and increase cautiously against a specific transfer, gait or personal-care goal.

Keep timing exact, avoid abrupt withdrawal and monitor hallucinations, delirium, sleepiness, nausea, posture and impulse-control symptoms.

Complications

01

Severe neuroleptic reaction

Rigidity, consciousness reduction, aspiration, autonomic failure and neuroleptic malignant syndrome may follow even modest antipsychotic exposure.

02

Falls, syncope and fracture

Parkinsonism, visuospatial error, posture hypotension and cognitive fluctuation combine to create recurrent injury. Anticipatory multidisciplinary prevention and review are therefore important.

03

Aspiration and malnutrition

Dysphagia, motor slowness, reduced smell and cognition impair safe intake and medication administration. Anticipatory multidisciplinary prevention and review are therefore important.

04

Sleep-related injury

REM-sleep enactment and daytime somnolence can injure the person or partner and impair carer sleep. Anticipatory multidisciplinary prevention and review are therefore important.

05

Carer and behavioural burden

Hallucinations, delusions, fluctuation and increasing motor care create anxiety, night supervision and crisis risk. Anticipatory multidisciplinary prevention and review are therefore important.

Monitoring and follow-up

  • Review pulse, posture, syncope, falls, weight and GI effects during cholinesterase titration.
  • Track hallucination distress, attention, IADLs, transfers, gait, swallow, sleep and actual carer supervision needs.
  • Use 4AT and medical assessment for acute deterioration rather than attributing all variability to DLB.
  • Reconcile Parkinson medicine timing at every transition and avoid missed or abruptly stopped levodopa.
  • Document neuroleptic sensitivity prominently across primary, ambulance, acute and care-home records.

Special situations

The one-year rule is naming convention

It separates DLB from Parkinson dementia clinically despite a shared alpha-synuclein spectrum.

Fluctuation needs magnitude

Ordinary fatigue is not the marked change in attention, coherence and alertness typical of DLB.

Hallucinations may not need drugs

Insightful non-distressing visions often respond to explanation, vision and environmental adjustment.

A normal memory screen can miss DLB

Visuospatial and executive dysfunction may dominate before severe episodic-memory loss.

Antipsychotic response can be catastrophic

Worsening rigidity or swallow after one dose is toxicity, not proof that more drug is needed.

Motor benefit has a price

Levodopa can improve mobility while worsening hallucination, posture and sleepiness.

Common pitfalls

  1. 01

    Calling chronic DLB fluctuation delirium without comparing with baseline, or missing superimposed delirium.

  2. 02

    Prescribing haloperidol for hallucinations before checking parkinsonism and DLB history.

  3. 03

    Using the term Parkinson dementia without establishing the motor-cognitive chronology.

  4. 04

    Interpreting a normal early memory score as excluding visuospatial-executive disease.

  5. 05

    Increasing levodopa without a functional target or hallucination and posture review.

  6. 06

    Equating fluctuation with global incapacity instead of assessing the decision in a clearer period.